Bayer’s Finerenone Shows Renal, CV Benefits In CKD/Type 2 Diabetes Patients – But Is It Enough?
Study shows risk reduction in both renal failure and cardiovascular events, but analysts question competitiveness versus SGLT-2 inhibitors and safety compared to earlier MR antagonists.
You may also be interested in...
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.